CRON Stock Overview
Operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for CRON from our risk checks.
My Notes
Capture your thoughts, links and company narrative
Cronos Group Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$1.95 |
| 52 Week High | CA$3.14 |
| 52 Week Low | CA$1.86 |
| Beta | 1.04 |
| 1 Month Change | -6.25% |
| 3 Month Change | -9.30% |
| 1 Year Change | -2.01% |
| 3 Year Change | -54.23% |
| 5 Year Change | -71.66% |
| Change since IPO | 1,081.82% |
Recent News & Updates
Cronos Group Is Probably Undervalued As Liquidity Swells
Dec 05Buy Cronos Stock Before It Surges Higher
Aug 20Cronos Group: An Intriguing Value Opportunity
Jun 17Recent updates
Cronos Group Is Probably Undervalued As Liquidity Swells
Dec 05Buy Cronos Stock Before It Surges Higher
Aug 20Cronos Group: An Intriguing Value Opportunity
Jun 17Cronos Stock: Attractive Now With Cannabis Legalization In Germany
Mar 04Cronos Group: Flush With Cash And Trading Below Book Value
Feb 11Cronos Group GAAP EPS of -$0.05 beats by $0.01, revenue of $23.1M misses by $5.25M
Aug 09Cronos Group: Too Much Cash, Too Soon - Making The Bear Case
Aug 01Cronos Group: High Hurdles
May 11Cronos Earnings: Cannabis Stock With 65% Net Cash And 51% Revenue Growth
Mar 01Cronos Group Late-Filed Q3-2021 Earnings Show Revenues From Synthetic Cannabinoids
Feb 22Cronos Group: Still No Reason To Own
Jan 22Cronos Group Strategic Investor Altria May Be About To Buy The Balance
Nov 08After Cronos Finally Invests In U.S. Cannabis, Is The Stock A Buy?
Aug 30Is Cronos Stock Worth Buying? Probably, But Patience Remains A Requirement
Jul 12Cronos Group stock rises 2.6% with acquisition of 10.5% stake in PharmaCann
Jun 14Cronos Group: Still Hasn't Launched
May 09Cronos Group Q1 Earnings Preview
May 06Cronos: The Most Confusing Cannabis Stock
Apr 28Cronos: Sitting On Your Hands Is Not A Winning Strategy
Jan 03Cronos Group (CRON) Investor Presentation - Slideshow
Nov 24Cronos Is A Buy With Increasing Revenues
Nov 18Cronos shares rise 5% on solid Q3 beat; top-line +96% boosted by advancement in Canadian/Israeli market
Nov 05Cronos: Failure To Launch
Nov 03Shareholder Returns
| CRON | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 1.0% | -1.5% | -2.4% |
| 1Y | -2.0% | 7.9% | 23.4% |
Return vs Industry: CRON underperformed the US Pharmaceuticals industry which returned 7.9% over the past year.
Return vs Market: CRON underperformed the US Market which returned 23.4% over the past year.
Price Volatility
| CRON volatility | |
|---|---|
| CRON Average Weekly Movement | 6.9% |
| Pharmaceuticals Industry Average Movement | 10.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CRON has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: CRON's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 356 | Mike Gorenstein | www.thecronosgroup.com |
Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.
Cronos Group Inc. Fundamentals Summary
| CRON fundamental statistics | |
|---|---|
| Market cap | US$742.22m |
| Earnings (TTM) | -US$47.56m |
| Revenue (TTM) | US$111.23m |
6.7x
P/S Ratio-15.6x
P/E RatioIs CRON overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CRON income statement (TTM) | |
|---|---|
| Revenue | US$111.23m |
| Cost of Revenue | US$87.81m |
| Gross Profit | US$23.42m |
| Other Expenses | US$70.98m |
| Earnings | -US$47.56m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.12 |
| Gross Margin | 21.06% |
| Net Profit Margin | -42.76% |
| Debt/Equity Ratio | 0% |
How did CRON perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 05:28 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Cronos Group Inc. is covered by 20 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Vahan Ajamian | Beacon Securities Limited |
| Tamy Chen | BMO Capital Markets Equity Research |
| Lisa Lewandowski | BofA Global Research |